The interferon-free regimen of ABT-450 ( a protease inhibitor ) , ritonavir , ombitasvir ( an NS5A inhibitor ) , dasabuvir ( a non-nucleoside polymerase inhibitor ) , and ribavirin has shown efficacy in patients with hepatitis C virus ( HCV ) genotype 1b infection-the most prevalent subgenotype worldwide .